What is Piracetam?

Piracetam is a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), a chemical messenger that slows down activity in your brain. Piracetam belongs to the racetam family of synthetic compounds characterized by their chemical backbone (a pyrrolidone ring).

Piracetam holds the distinction of being the first racetam ever produced. It was synthesized in 1964 by scientists at the Belgian pharmaceutical company UCB. By the early 1970s, Piracetam was approved in Europe for the treatment of vertigo and age-related disorders. [R]

Over the decades, various studies have been conducted on Piracetam. These studies have shown that it potentially possesses nootropic, neuroprotective, and anticonvulsant effects. Piracetam has also demonstrated the potential ability to decrease the number of breath-holding spells in children. [R][R]

A systematic review of these studies reported that Piracetam could potentially cross the blood-brain barrier. The nootropic has a half-life of between 5 and 8 hours, much longer than other Piracetam-like compounds, such as phenylpiracetam and aniracetam. [R]

How does Piracetam Work?

Although its exact working mechanism remains unknown, Piracetam has been shown to:

• May Increase Acetylcholine Activity in the Brain [R]
• May Alleviate Mitochondrial Dysfunction [R]
• May Enhance energy metabolism [R]
• May Improve Neuroplasticity [R]

Piracetam Research

Various clinical and animal studies have documented Piracetam’ efficacy in multiple conditions, such as cognitive disorders, dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. There is also concrete evidence of Piracetam’s potential in restoring cell membrane fluidity. [R]

A few human studies suggest that Piracetam may potentially reduce the number of “breath-holding spells” in children and improve cognition in patients that underwent coronary bypass surgery. In a preclinical study, it reduced neurodegeneration in the brains of alcohol-withdrawn rats. [R][R][R]

Here’s a summary of the existing research on Piracetam:

Piracetam and Dyslexia

A clinical trial investigated the effects of Piracetam treatment on dyslexic patients and healthy students. Both groups were potentially given 800mg of Piracetam capsules or a placebo. Final results showed that verbal learning may have increased by up to 15% in dyslexic patients, and by 8.6% in healthy students. [R]

Similarly, in a 36-week double-blind study, children that potentially administered 3.3 g Piracetam dosage per day potentially demonstrated faster reaction times. Aside from that, the Piracetam group found it easier to recognize language-related test prompts, suggesting improved feature analysis. [R]

Piracetam and Mild Cognitive Disorders

In 104 patients with mild cognitive impairment or dementia, Piracetam treatment had the potential to improve memory and psychomotor functions. It was reported that these potential improvements in cognitive performance appeared after a few weeks of Piracetam administration. [R]

A meta-analysis of 19 studies was conducted in which patients suffering from dementia or cognitive impairment were treated with Piracetam. Results showed that Piracetam may potentially be highly effective in a diverse group of older adults with central nervous system CNS disorders. [R]

Piracetam and Post-Stroke Recovery

According to one pilot study, Piracetam treatment for 12 weeks had the potential for improved aphasia symptoms in patients recovering from a specific stroke. However, the unavailability of patients after the study’s completion means it cannot be confirmed whether this effect remained post-treatment. [R]

A systematic review of 7 randomized, clinical trials in which post-stroke patients underwent Piracetam treatment was carried out. It was noted that Piracetam potentially rehabilitations overall language impairment. The nootropic was also found to potentially benefit written language ability in patients. [R]

Piracetam and Schizophrenia

A clinical study demonstrated that adding Piracetam to existing treatment may have improved the behavioral and cognitive functions in schizophrenic patients. Schizophrenia typically begins in adulthood and affects every 35 people out of 100,000. Symptoms include hallucinations and delusions. [R]

Schizophrenic patients are at an increased risk of tardive dyskinesia, a condition characterized by involuntary movement of the tongue, lips, face, trunk, and legs. In a placebo-controlled trial, Piracetam treatment may have potentially effectively reduced TD symptoms in people with schizophrenia. [R]

Piracetam and Mental Performance

A double-blind placebo-controlled trial explored the effects of Placebo administration on the mental performance of 18 aging, non-deteriorated individuals. All the study’s participants were administered either this compound or placebo before being asked to complete various tasks. [R]

In most of the tasks, the subjects on Piracetam potentially did better than their counterparts on placebo. These findings indicate that Piracetam may potentially be used to treat individuals with reduced mental performance, possibly due to disturbed alertness.

Piracetam and Myoclonus Epilepsy

According to a double-blind, crossover study, Piracetam may be effective and well tolerated for the treatment of myoclonus epilepsy. In addition, the study showed that a dose of 24 g may be highly beneficial and more effective than lower doses. [R]

Similarly, in another clinical study, the addition of Piracetam to existing anti-epileptic treatment potentially caused marked and sometimes spectacular improvements in myoclonus symptoms. The authors recommended that Piracetam should be potentially be considered a first-line compound for cortical myoclonus. [R]

Piracetam and Fetal Distress

A 1998 review investigated the effects of Piracetam on suspected fetal distress in labor. The review enlisted one trial in which 96 women were randomized to receive either Piracetam or a placebo. It was reported that Piracetam treatment may have potentially reduced the need for a cesarean section. [R]

More evidence is needed to evaluate the use of this drug for fetal distress in labor.

Piracetam Side Effects

Owing to its status as the first-ever nootropic, Piracetam has attracted multiple clinical trials and animal and cell-based studies. These studies have shown that Piracetam is potentially generally safe. In long-term studies, doses of up to 24 grams daily potentially didn’t produce any adverse effects. [R][R]

That said, in a pooled analysis of 91 double-blind, placebo-controlled studies, weight gain, nervousness, depression, and asthenia were potentially slightly increased with the nootropic. However, the potential incidence of each of these events was less than 2%. Speak to your doctor to know more. [R][R]

PureRawz doesn’t sell Piracetam for human consumption.

FAQs

What is the Half-Life of Piracetam?

Piracetam (molecular formula C6H10N2O2) has a half-life ranging from 5 to 8 hours.

Is Piracetam Legal?

Piracetam is legal in many European countries for the treatment of myoclonus epilepsy. In the USA, the Food and Drug Administration (FDA) is yet to approve it. However, you can legally buy Piracetam for laboratory and research purposes.

Where to Buy Piracetam Online?

PureRawz is the best place to buy high-quality Piracetam online.

In order to be the best supplier of research peptides, we provide reference materials with every product we sell. All of our products come with an independent, third-party-issued Certificate of Analysis for identification, purity, and concentration.

We offer free international shipping on all orders above $100. You can pay for your purchase through various methods, including PayPal and Bitcoin. Click on ‘Reviews’ to check what existing customers have to say about our products and customer service.

Summary

Piracetam is a nootropic with novel clinical applications for various conditions. Human studies have shown that it may potentially help with post-stroke recovery, reduce the symptoms of schizophrenia and myoclonus epilepsy, and improve memory and learning in patients with mild cognitive impairment.